Creating a new adjuvant system to improve influenza vaccines
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
This study is working on a new way to boost the effectiveness of flu vaccines by using a special combination of ingredients that helps your immune system respond better, and it's aimed at making vaccines even more helpful for everyone.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Inimmune Corporation NIH-funded |
| Lab location | 1 site (Missoula, United States) |
| Project ID | NIH-11127341 on NIH RePORTER |
What this research studies
This research focuses on developing a synthetic adjuvant system designed to enhance the immune response to influenza vaccines. The approach involves combining a novel synthetic TLR4 agonist with a semi-synthetic saponin to create a more effective vaccine formulation. Pre-clinical trials have shown promising results in generating strong antibody and T-cell responses when used with flu antigens. The goal is to optimize and produce this adjuvant under good manufacturing practices to prepare for clinical trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at risk of influenza infection, including those with compromised immune systems or chronic health conditions.
Not a fit: Patients who are not at risk for influenza or those who have already received effective vaccinations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective influenza vaccines that provide better protection against the virus.
How similar studies have performed: Other research has shown success with similar adjuvant systems, indicating a promising avenue for enhancing vaccine efficacy.
Where this research is happening
Missoula, United States
- Inimmune Corporation — Missoula, United States (Active)
Researchers
- Principal investigator: Burkhart, David — Inimmune Corporation
- Study coordinator: Burkhart, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.